Impact of Treatment Related Neutropenia on Response to Palbociclib in Metastatic Hormone Positive, her2neu Negative Breast Cancer

Key Points

• To assess the effect of treatment-related neutropenia on the response to palbociclib in breast cancer patients.
• Examined neutropenia levels in patients receiving palbociclib treatment.
• Evaluated dose reduction effects on treatment outcomes.
• Analyzed disease progression in relation to neutropenia.
• Neutropenia due to palbociclib did not alter disease outcomes.
• Dose reductions associated with neutropenia had no significant effect on treatment efficacy.